Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.

Koprivnikar J, McCloskey J, Faderl S.

Onco Targets Ther. 2017 Mar 6;10:1413-1422. doi: 10.2147/OTT.S106810. eCollection 2017. Review.

2.

Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase.

Boissel N, Sender LS.

J Adolesc Young Adult Oncol. 2015 Sep;4(3):118-28. doi: 10.1089/jayao.2015.0014. Review.

3.

Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.

Douer D, Aldoss I, Lunning MA, Burke PW, Ramezani L, Mark L, Vrona J, Park JH, Tallman MS, Avramis VI, Pullarkat V, Mohrbacher AM.

J Clin Oncol. 2014 Mar 20;32(9):905-11. doi: 10.1200/JCO.2013.50.2708. Epub 2014 Feb 10.

PMID:
24516026
4.
5.

Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.

Aldoss I, Douer D, Behrendt CE, Chaudhary P, Mohrbacher A, Vrona J, Pullarkat V.

Eur J Haematol. 2016 Apr;96(4):375-80. doi: 10.1111/ejh.12600. Epub 2015 Jun 25.

PMID:
26095294
6.

Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.

Bade NA, Lu C, Patzke CL, Baer MR, Duong VH, Law JY, Lee ST, Sausville EA, Zimrin AB, Duffy AP, Lawson J, Emadi A.

J Oncol Pharm Pract. 2019 Mar 27:1078155219838316. doi: 10.1177/1078155219838316. [Epub ahead of print]

PMID:
30917738
7.
8.

Acute lymphoblastic leukaemia: a guide to asparaginase and pegaspargase therapy.

Ettinger LJ, Ettinger AG, Avramis VI, Gaynon PS.

BioDrugs. 1997 Jan;7(1):30-9.

PMID:
18031078
9.

Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?

Douer D.

Best Pract Res Clin Haematol. 2008 Dec;21(4):647-58. doi: 10.1016/j.beha.2008.08.004. Review.

PMID:
19041604
10.

Peg-asparaginase for acute lymphoblastic leukemia.

Rytting M.

Expert Opin Biol Ther. 2010 May;10(5):833-9. doi: 10.1517/14712591003769808. Review.

PMID:
20345338
11.
12.

Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.

Lau KM, Saunders IM, Goodman A.

J Oncol Pharm Pract. 2019 Mar 1:1078155219833438. doi: 10.1177/1078155219833438. [Epub ahead of print]

PMID:
30823860
13.

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia.

Egler RA, Ahuja SP, Matloub Y.

J Pharmacol Pharmacother. 2016 Apr-Jun;7(2):62-71. doi: 10.4103/0976-500X.184769. Review.

14.

Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.

Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB.

Leukemia. 1999 Mar;13(3):335-42.

PMID:
10086723
16.

Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.

Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI.

Clin Cancer Res. 2004 Aug 15;10(16):5335-41.

17.

Pegaspargase: an alternative?

Holle LM.

Ann Pharmacother. 1997 May;31(5):616-24. Review.

PMID:
9161659
18.

Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.

Winter SS, Holdsworth MT, Devidas M, Raisch DW, Chauvenet A, Ravindranath Y, Ducore JM, Amylon MD.

Pediatr Blood Cancer. 2006 Feb;46(2):179-86.

PMID:
16007607
19.

Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.

Rizzari C, Putti MC, Colombini A, Casagranda S, Ferrari GM, Papayannidis C, Iacobucci I, Abbenante MC, Sartor C, Martinelli G.

Hematol Rep. 2014 Sep 30;6(3):5554. doi: 10.4081/hr.2014.5554. eCollection 2014 Aug 26. Review.

20.

Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Keilani T, Lane AR, Loh ML, Reaman GH, Adamson PC, Wood B, Wood C, Zheng HW, Raetz EA, Winick NJ, Carroll WL, Hunger SP.

J Clin Oncol. 2014 Dec 1;32(34):3874-82. doi: 10.1200/JCO.2014.55.5763. Epub 2014 Oct 27.

Supplemental Content

Support Center